Teva Pharmaceutical Indus... (TEVA)
NYSE: TEVA
· Real-Time Price · USD
17.57
0.03 (0.17%)
At close: Aug 15, 2025, 9:59 AM
Teva Pharmaceutical Industries Income Statement
Financials in USD. Fiscal
year is
January - December.
Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 4.18B | 3.89B | 4.23B | 4.33B | 4.16B | 3.83B | 4.46B | 3.85B | 3.88B | 3.66B | 3.88B | 3.6B | 3.79B | 3.66B | 4.1B | 3.89B | 3.91B | 3.98B |
Cost of Revenue | 2.07B | 2.01B | 2.11B | 2.18B | 2.14B | 2.05B | 2.04B | 2B | 2.08B | 2.08B | 2.11B | 1.93B | 1.99B | 1.92B | 2.05B | 2.09B | 2.04B | 2.1B |
Gross Profit | 2.1B | 1.88B | 2.12B | 2.15B | 2.02B | 1.78B | 2.42B | 1.85B | 1.8B | 1.58B | 1.77B | 1.67B | 1.79B | 1.74B | 2.05B | 1.79B | 1.87B | 1.88B |
Operating Income | 455M | 519M | -29M | -51M | 814M | 656M | 722M | 355M | -646M | -13M | 743M | 672M | -949M | -713M | 78M | 623M | 582M | 434M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 226M | n/a | 227M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | 203M | 294M | -247M | -324M | -246M | -467M | 473M | 75M | -914M | -272M | -1.1B | 166M | -1.16B | -971M | -175M | 382M | 308M | 144M |
Net Income | 282M | 214M | -217M | -437M | -845M | -139M | 429M | 80M | -863M | -220M | -1.22B | 56M | -232M | -955M | -159M | 292M | 207M | 77M |
Selling & General & Admin | 959M | 919M | 952M | 924M | 939M | 886M | 902M | 844M | 910M | 842M | 838M | 822M | 907M | 880M | 908M | 888M | 857M | 875M |
Research & Development | 244M | 247M | 248M | 240M | 269M | 242M | 227M | 253M | 240M | 234M | 210M | 175M | 228M | 225M | 244M | 222M | 248M | 254M |
Other Expenses | n/a | 192M | 949M | n/a | 1M | n/a | n/a | 9M | n/a | 520M | n/a | 1M | n/a | 1.35B | n/a | n/a | n/a | 5M |
Operating Expenses | 1.2B | 1.36B | 2.15B | 1.16B | 1.21B | 1.13B | 1.13B | 1.1B | 1.15B | 1.6B | 1.05B | 997M | 1.14B | 2.45B | 1.15B | 1.11B | 1.1B | 1.13B |
Interest Expense | n/a | 225M | 239M | 272M | 241M | 250M | 260M | 280M | 268M | 260M | 245M | 252M | 211M | 258M | 180M | 241M | 240M | 290M |
Selling & Marketing Expenses | 654M | 622M | 650M | 626M | 656M | 608M | 610M | 576M | 603M | 546M | 549M | 539M | 594M | 584M | 632M | 597M | 615M | 585M |
Cost & Expenses | 3.28B | 3.37B | 4.26B | 3.35B | 3.35B | 3.18B | 3.17B | 3.1B | 3.23B | 3.67B | 3.16B | 2.92B | 3.13B | 4.37B | 3.2B | 3.2B | 3.14B | 3.23B |
Income Tax Expense | -79M | 74M | 28M | 69M | 630M | -52M | 41M | -12M | -16M | -19M | 154M | 107M | -900M | 2M | -24M | 76M | 98M | 62M |
Shares Outstanding (Basic) | 1.15B | 1.14B | 1.13B | 1.13B | 1.13B | 1.12B | 1.12B | 1.12B | 1.12B | 1.11B | 1.11B | 1.11B | 1.11B | 1.11B | 1.1B | 1.1B | 1.1B | 1.1B |
Shares Outstanding (Diluted) | 1.16B | 1.16B | 1.13B | 1.13B | 1.13B | 1.12B | 1.14B | 1.14B | 1.12B | 1.11B | 1.11B | 1.12B | 1.11B | 1.11B | 1.1B | 1.11B | 1.11B | 1.11B |
EPS (Basic) | 0.25 | 0.19 | -0.19 | -0.39 | -0.75 | -0.12 | 0.41 | 0.07 | -0.77 | -0.2 | -1.1 | 0.05 | -0.21 | -0.86 | -0.14 | 0.26 | 0.19 | 0.07 |
EPS (Diluted) | 0.24 | 0.18 | -0.19 | -0.39 | -0.75 | -0.12 | 0.41 | 0.07 | -0.77 | -0.2 | -1.1 | 0.05 | -0.21 | -0.86 | -0.14 | 0.26 | 0.19 | 0.07 |
EBITDA | 455M | 763M | 261M | 210M | 254M | 45M | 1.52B | 1.04B | -382M | 292M | -488M | 994M | -592M | -390M | 1.16B | 1.04B | 582M | 810M |
EBIT | n/a | 519M | -8M | -52M | -5M | -227M | 694M | 344M | -655M | -12M | -892M | 418M | -950M | -713M | -89M | 623M | 609M | 434M |
Depreciation & Amortization | n/a | 244M | 269M | 259M | 259M | 272M | 266M | 283M | 300M | 304M | 306M | 321M | 358M | 323M | 320M | 329M | 307M | 376M |